|
Real-world adoption of PD-L1 testing in metastatic urothelial carcinoma. |
|
|
Stock and Other Ownership Interests - Nektar |
Honoraria - AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Seagen |
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology |
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst) |
|
|
Employment - Kantar Health |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Other Relationship - AstraZeneca |
|
|
Employment - Kantar Health |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
|
|
Employment - Kantar Health |
Research Funding - AstraZeneca |
|
|
No Relationships to Disclose |